Imfinzi
(durvalumab)

Fax completed form to: (855) 840-1678
If this is an URGENT request, please call (800) 882-4462

PHYSICIAN INFORMATION			PATIENT INFORMATION		
* Physician's Name:			*Due to privacy regulations we will not be able to respond via fax with the outcome of our review unless all asterisked (*) items on this form are completed.*		
Specialty:	* DEA, NPI or TIN:				
Office Contact Person:			* Patient Name:		
Office Phone:			* Cigna ID:	* Date of Birth:	
Office Fax:			* Patient Street Address:		
Office Street Address:			City	State	Zip
City	State	Zip	Patient Phone:		

Urgency:
☐ Standard
☐ Urgent (In checking this box, I attest to the fact that applying the standard review time frame may seriously jeopardize the customer's life, health, or ability to regain maximum function)

Medication requested:
☐ Imfinzi 120mg/2.4ml vial
☐ Imfinzi 500mg/10ml vial

Dose and Quantity: Duration of therapy: ICD10:

Frequency of therapy: What is your patient's current weight?

Where will this medication be obtained?
☐ Accredo Specialty Pharmacy**
☐ Prescriber's office stock (billing on a medical claim form)
☐ Other (please specify):
☐ Retail pharmacy
☐ Home Health / Home Infusion vendor
***Cigna's nationally preferred specialty pharmacy*

***Medication orders can be placed with Accredo via E-prescribe - Accredo (1620 Century Center Pkwy, Memphis, TN 38134-8822 | NCPDP 4436920), Fax 888.302.1028, or Verbal 866.759.1557*

Facility and/or doctor dispensing and administering medication:
Facility Name: State: Tax ID#:
Address (City, State, Zip Code):

***NOTE:** Per some Cigna plans, infusion of medication MUST occur in the lowest cost, medically appropriate setting*

Is this infusion occurring in a facility affiliated with hospital outpatient setting? ☐ Yes ☐ No

If yes- Is this patient a candidate for re-direction to an alternate setting (such as AIS, MDO, home) with assistance of a Specialty Care Option Case Manager? ☐ Yes ☐ No (provide medical necessity rationale):

Is your patient a candidate for home infusion? Yes ☐ No ☐
Does the physician have an in-office infusion site? Yes ☐ No ☐

Is the requested medication for a chronic or long-term condition for which the prescription medication may be necessary for the life of the patient? ☐ Yes ☐ No

Diagnosis related to use:
☐ biliary tract cancer (BTC)
☐ endometrial cancer
☐ hepatocellular carcinoma (HCC)
☐ non-small cell lung cancer (NSCLC)
☐ small cell lung cancer (SCLC)
☐ urothelial carcinoma (UCC, transitional cell carcinoma [TCC])
☐ other (please specify):

Clinical Information:

(if BTC) Will/is this medication (be)ing given in combination with gemcitabine and cisplatin? ☐ Yes ☐ No

(if NSCLC) Does your patient have locally-advanced, unresectable disease? ☐ Yes ☐ No
(if NSCLC) Has your patient's disease progressed following chemoradiotherapy? ☐ Yes ☐ No

(if BTC or UCC) Does your patient have locally advanced or metastatic disease? ☐ Yes ☐ No
(if UCC) Will this medication be used as single agent therapy? ☐ Yes ☐ No
(if UCC) Did your patient have disease progression during or after treatment with platinum-based chemotherapy (carboplatin, cisplatin)? ☐ Yes ☐ No

(if HCC) Does the patient have unresectable disease? Note: Answer 'yes' if patient has uHCC. ☐ Yes ☐ No

(if HCC) Will/Is this medication (be)ing used in combination with tremelimumab-actl (Imjudo) for this diagnosis? ☐ Yes ☐ No

(if SCLC) Is the patient's disease considered to be extensive stage? Note: Answer 'yes' if patient has ES-SCLC. ☐ Yes ☐ No

(if SCLC) Is this medication being used as part of first line therapy for this diagnosis? ☐ Yes ☐ No
(if SCLC) Will/Was this medication (be) used in combination with etoposide (Etopophos, Toposar) and either carboplatin or cisplatin for the first 4 cycles of therapy? ☐ Yes ☐ No

(if endometrial) Is/Was this medication (being) used in combination with carboplatin and paclitaxel, followed by the requested medication as single agent therapy? ☐ Yes ☐ No

(if endometrial) Does the patient have primary advanced or recurrent disease? ☐ Yes ☐ No

(if endometrial) Is the patient's disease considered mismatch repair deficient (dMMR)? ☐ Yes ☐ No

Additional Information: *(including disease stage, prior therapy, performance status, and names/doses/admin schedule of any agents to be used concurrently):*

Attestation: I attest the information provided is true and accurate to the best of my knowledge. I understand that the Health Plan or insurer its designees may perform a routine audit and request the medical information necessary to verify the accuracy of the information reported on this form.

Prescriber Signature:____ **Date:**____________________

Save Time! Submit Online at: www.covermymeds.com/main/prior-authorization-forms/cigna/ or via SureScripts in your EHR.

Our standard response time for prescription drug coverage requests is 5 business days. If your request is urgent, it is important that you call us to expedite the request. View our Prescription Drug List and Coverage Policies online at cigna.com.

v091524

"Cigna" is a registered service mark, and the "Tree of Life" logo is a service mark, of Cigna Intellectual Property, Inc., licensed for use by Cigna Corporation and its operating subsidiaries. All products and services are provided by or through such operating subsidiaries and not by Cigna Corporation. Such operating subsidiaries include, for example, Cigna Health and Life Insurance